Diagonal Therapeutics
PrivateLast Round
Series B
Jan 8, 2026
Total Funding Raised
$253M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Diagonal Therapeutics is a biotechnology company that discovers and develops agonist antibodies using a proprietary platform to address the root causes of severe diseases such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diagonal Therapeutics Comparables
Compare Diagonal Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vaderis Therapeutics | 81% | |
| Tectonic Therapeutic | 79% | |
| AltruBio | 71% |
Diagonal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 8, 2026 | ||||
| Series A | Apr 3, 2024 |
Key People
Founding team and executive leadership
Diagonal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| Janus Henderson Group | Series B |
| RA Capital Advisors | Series A |
| Balyasny Asset Management L.P. | Series B |
| RA Capital Management | Series A, Series B |
| VF Partners | Series A |
| Deep Track Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2026
Grew 23% QoQ from 31 to 38 employees.
- Aug 20, 2026
Monthly visitors increased 66% MoM.
Recent news
Latest coverage and updates
- is_developingAug 12, 2026
Diagonal Therapeutics, Inc. is developing DIAG723.
Diagonal Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Diagonal Therapeutics's valuation, stock price, and market status.
Is Diagonal Therapeutics a public or private company?
Diagonal Therapeutics is a private company.
What is the current stock price of Diagonal Therapeutics?
Diagonal Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Diagonal Therapeutics worth (valuation)?
Valuation information for Diagonal Therapeutics is not publicly available.
Can I buy Diagonal Therapeutics stock?
Diagonal Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Diagonal Therapeutics's last funding round?
Diagonal Therapeutics's most recent funding round was Series B on January 8, 2026.
Who are the main investors in Diagonal Therapeutics?
Key investors in Diagonal Therapeutics include Janus Henderson Group, VF Partners, BVF Partners L.P., Sanofi Ventures, Atlas Venture.
Will Diagonal Therapeutics IPO soon?
No public IPO plans have been announced for Diagonal Therapeutics.
How can I track Diagonal Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Diagonal Therapeutics's secondary market activity and sign up for updates.